Literature DB >> 438050

Canine hyperadrenocorticism: pretreatment clinical and laboratory evaluation of 117 cases.

G V Ling, G H Stabenfeldt, K M Comer, D H Gribble, R D Schechter.   

Abstract

The physical findings, clinical signs, age, breed and sex distributions, and laboratory data of 117 dogs with untreated Cushing's syndrome were reviewed. Poodles, Dachshunds, and Boxers of all ages were found to be at increased risk, as were dogs of all breeds greater than or equal to 6 years old. Polydipsia, polyuria, progressive bilaterally symmetric alopecia, and abdominal distention were the most frequently observed clinical signs and physical findings. Lymphopenia, eosinopenia, above normal values of serum alkaline phosphatase, serum cholesterol, and sulfobromphthalein dye retention, and below normal urine specific gravity were the most frequent abnormalities found in the laboratory data. About 50% of the dogs had urinary tract infections. Final diagnosis was established on the basis of abnormally high plasma corticosteroid values in response to an intramuscular injection of adrenocorticotropic hormone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438050

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  15 in total

1.  Hyperadrenocorticism in three teddy bear hamsters.

Authors:  L B Bauck; J P Orr; K H Lawrence
Journal:  Can Vet J       Date:  1984-06       Impact factor: 1.008

2.  Frequency and risk factors for naturally occurring Cushing's syndrome in dogs attending UK primary-care practices.

Authors:  I Schofield; D C Brodbelt; S J M Niessen; D B Church; R F Geddes; D G O'Neill
Journal:  J Small Anim Pract       Date:  2021-12-08       Impact factor: 1.669

3.  Letter to the editor.

Authors:  Joerg M Steiner; Panagiotis Xenoulis; Jan S Suchodolski
Journal:  J Vet Intern Med       Date:  2014 Nov-Dec       Impact factor: 3.333

4.  Clinical Relationship between Cholestatic Disease and Pituitary-Dependent Hyperadrenocorticism in Dogs: A Retrospective Case Series.

Authors:  K-H Kim; S-M Han; K-O Jeon; H-T Kim; Q Li; M-O Ryu; W-J Song; S-C Park; H-Y Youn
Journal:  J Vet Intern Med       Date:  2017-01-08       Impact factor: 3.333

Review 5.  New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.

Authors:  Mariana Fuertes; Julieta Tkatch; Josefina Rosmino; Leandro Nieto; Mirtha Adriana Guitelman; Eduardo Arzt
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-24       Impact factor: 5.555

6.  Evaluation of individual low-dose dexamethasone suppression test patterns in naturally occurring hyperadrenocorticism in dogs.

Authors:  Michael Bennaim; Robert E Shiel; Christopher Forde; Carmel T Mooney
Journal:  J Vet Intern Med       Date:  2018-03-02       Impact factor: 3.333

7.  Cortisol secretion after adrenocorticotrophin (ACTH) and dexamethasone tests in healthy female and male dogs.

Authors:  Paula Pessina; Andrea Fernández-Foren; Enrique Cueto; Luis Delucchi; Victor Castillo; Ana Meikle
Journal:  Acta Vet Scand       Date:  2009-08-17       Impact factor: 1.695

8.  Evaluation of 1,2-O-dilauryl-rac-glycero glutaric acid-(6'-methylresorufin) ester (DGGR) and 1,2-diglyceride lipase assays in dogs with naturally occurring hypercortisolism.

Authors:  Guido Linari; Francesco Dondi; Sofia Segatore; Kateryna Vasylyeva; Nikolina Linta; Marco Pietra; Rodolfo O Leal; Federico Fracassi
Journal:  J Vet Diagn Invest       Date:  2021-06-02       Impact factor: 1.569

9.  Clinical findings, diagnostic test results, and treatment outcome in cats with spontaneous hyperadrenocorticism: 30 cases.

Authors:  S Y Valentin; C C Cortright; R W Nelson; B M Pressler; D Rosenberg; G E Moore; J C Scott-Moncrieff
Journal:  J Vet Intern Med       Date:  2014-01-16       Impact factor: 3.333

10.  ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.

Authors:  Daniel K Langlois; Michele C Fritz; William D Schall; N Bari Olivier; Rebecca C Smedley; Paul G Pearson; Marc B Bailie; Stephen W Hunt
Journal:  BMC Endocr Disord       Date:  2018-05-02       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.